Evidence map›Paper›PMID 34504567›Full record

ArticleExperimental and therapeutic medicine2021

Clinical significance of serum matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in the first phase of burn trauma evolution.

Adina Elena Stanciu, Adina Zamfir-Chiru-Anton, Marcel Marian Stanciu, Mirela Gherghe, Razvan Hainarosie, Florentina Ligia Furtunescu, Dan Cristian Gheorghe

Open access · diamondAbstract read
In one paragraph

Article in Experimental and therapeutic medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Adina Elena StanciuDepartment of Carcinogenesis and Molecular Biology, 'Prof. Dr. Alexandru Trestioreanu' Institute of Oncology, 022328 Bucharest, Romania.
Adina Zamfir-Chiru-AntonENT Department, 'Grigore Alexandrescu' Children's Emergency Hospital, 011743 Bucharest, Romania.
Marcel Marian StanciuElectrical Engineering Faculty, 'Politehnica' University, 060042, Bucharest, Romania.
Mirela GhergheDepartment of Nuclear Medicine, 'Prof. Dr. Alexandru Trestioreanu' Institute of Oncology, 022328 Bucharest, Romania.
Razvan HainarosieENT Department, 'Prof. Dr. Dorin Hociota' Institute of Phonoaudiology and Functional ENT and Cervicofacial Surgery, 050751 Bucharest, Romania.
Florentina Ligia FurtunescuDepartment of Complementary Sciences, 'Carol Davila' University of Medicine and Pharmacy, 050463 Bucharest, Romania.
Dan Cristian GheorgheENT Department, 'Carol Davila' University of Medicine and Pharmacy, 050463 Bucharest, Romania.
Carol Davila University of Medicine and Pharmacy · ROInstitutul Oncologic Bucuresti · ROClinical Emergency Hospital Bucharest · ROUniversitatea Națională de Știință și Tehnologie Politehnica București · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

No prospective study has specifically examined the serum levels of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in the early shock phase of burn-injured patients. Thus, we aimed to detect early changes, activity dynamics, and the predictive value of MMP-9, TIMP-1, and the MMP-9/TIMP-1 ratio to better understand the early repair mechanisms for the development of future therapies for patients with thermal burns. Twenty-five patients with a total body surface area (TBSA) affected by burn <25%, and 30 healthy subjects were enrolled in the study. Serum levels of MMP-9 and TIMP-1 were determined by the ELISA method. Our results showed that MMP-9 concentrations increased immediately after injury and remained on a plateau. In contrast, TIMP-1 showed an upward trend throughout the 7-day study period, and the time course of the MMP-9/TIMP-1 ratio followed the inverse dynamics of TIMP-1. Analysis of the areas under the receiver operating characteristic (ROC) curves (AUC) showed that patients with burn wounds tended to have a MMP-9 value higher than 421.5 ng/ml (AUC=0.979), TIMP-1 value higher than 231.6 ng/ml (AUC=0.908), and MMP-9/TIMP-1 ratio higher than 2.31 (AUC=0.959) (P<0.001). Our findings suggest that although the variations in the two biomarkers were different regarding the time of the initial insult, their ratio is a specific and sensitive indicator of burn evolutivity in patients with a TBSA affected by a burn <25%.

Indexed as

burn injuryMMP-9MMP-9/TIMP-1 ratioROC curveTIMP-1

Identifiers

PMID34504567
PMCPMC8383775
OpenAlexW3191691520

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.